Life Sciences industry leader joins the region’s Life Science & Healthcare membership organisation
Cambridge, UK: 10 April 2024
We create a place where people can grow, be their best, be safe, and feel welcome, valued and included. We offer a competitive salary, an annual bonus based on company performance, healthcare and wellbeing programmes, pension plan membership, and shares and savings programme.
We embrace modern work practises; our Performance with Choice programme offers a hybrid working model, empowering you to find the optimal balance between remote and in-office work.
We are seeking an internationally recognised scientific leader to direct the Wellcome Sanger Institute’s Somatic Genomics Programme, one of our flagship research domains. This role offers the opportunity to define and deliver a bold, long-term scientific vision for understanding how somatic mutations arise, accumulate and shape human health across the lifespan.
At AstraZeneca, we're united by a bold ambition: to push the boundaries of science and deliver life-changing medicines to patients worldwide. As a global, science-led biopharmaceutical company, we transform pioneering research into breakthrough treatments across oncology, cardiovascular, respiratory, and rare diseases. Here, your talent will contribute to innovations that truly matter—helping us reimagine healthcare and create a healthier future for all!
Introduction to role:
Your new role - The Director of Marketing, Government, Funder & Non-profit (GFN) is a pivotal role responsible for driving pipeline growth and strengthening Digital Science’s brand across the region. Reporting to the VP of GFN Marketing, this role leads the development and execution of an integrated marketing strategy for public sector and non-profit audiences.
Metabolic instability is a key challenge in developing peptide therapeutics, and factors like rapid clearance and complex, multi-pathway biotransformation can further limit their effectiveness. Understanding and addressing these hurdles can unlock the full potential of peptide drugs, enabling them to reach challenging biological targets, support rational chemical design, and achieve clinical success. This webinar presents an integrated mechanism–analytics–design perspective to tackle these challenges and accelerate peptide drug discovery.
Poorly soluble molecules face unique challenges that can slow development and limit clinical success. Early formulation decisions are critical for determining bioavailability, in vivo exposure and the speed to IND submission and first-in-human studies. This webinar will show how tailored early-phase strategies, aligned with molecule properties and clinical stage, can overcome solubility, bioavailability limitations and related formulation challenges.
Potential to become a new modality in the treatment of ulcerative colitis offering prolonged remission without immune suppression
The study which compared MB310, a precision microbiome medicine, with placebo in 29 ulcerative colitis (UC) patients met its primary and secondary objectives to demonstrate safety, efficacy and engraftment:
Efficacy:
BioTrinity is attended by an ever-evolving international audience of c.850 delegates, comprising a mix of academic entrepreneurs, early stage and emerging life sciences R&D companies, funders & investors, big pharma teams, charities & research bodies, government, regulatory bodies, along with professional services and expert supporters to the industry.
This year’s event will feature a diverse global audience, international market showcases, dedicated investor networking, and presentations from the most promising life sciences companies.